ClinConnect ClinConnect Logo
Search / Trial NCT06870110

Brain Training for Substance Use Disorders

Launched by NEUROTYPE INC. · Mar 5, 2025

Trial Information

Current as of October 22, 2025

Recruiting

Keywords

Biofeedback Neurofeedback Electroencephalogram Addiction Substance Use Disorder Opioid Use Disorder Attention Emotion Regulation Event Related Potential

ClinConnect Summary

This clinical trial, titled "Brain Training for Substance Use Disorders," is examining a new approach to help people struggling with opioid use disorder (OUD). Participants will play specially designed games that focus on improving their attention towards everyday activities that don't involve drugs. The games are paired with a system that monitors brain activity through a device called an EEG, which helps adjust the game's difficulty based on how the player performs. This study aims to see if this type of brain training can support recovery from opioid addiction.

To participate, individuals must be between the ages of 18 and 65, currently receiving treatment for opioid use disorder, and able to understand and provide consent. Control participants—those who do not have OUD but match the age and gender of participants with OUD—are also welcome. All participants should be able to read at least at a sixth-grade level and provide their contact information for follow-ups. It’s important to note that pregnant individuals, those with certain serious neurological issues, and those currently using opioids or other drugs are not eligible. Participants can expect to engage in interactive gameplay while providing valuable data that could help improve treatment methods for opioid addiction.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • OUD patient participants:
  • Admitted into chemical treatment with opioid use being a reason for treatment;
  • DSM-IV-TR diagnosis of OUD;
  • Ability to provide informed consent;
  • A minimum of a 6th grade reading level; and
  • Able and willing to provide own contact information for follow-up visit(s).
  • Control participants:
  • Age- and gender-matched to an OUD patient participant in the study;
  • Ability to provide informed consent;
  • A minimum of a 6th grade reading level;
  • Able and willing to provide own contact information for follow-up visit(s).
  • Exclusion Criteria:
  • OUD patient participants:
  • Refusal or inability to consent;
  • Pregnant;
  • History of serious neurological illness (e.g., Chronic seizure disorder, Wernicke-Korsakoff Syndrome, Epilepsy, Any history of seizures not caused by withdrawal from substances, Other \[please specify\]);
  • Inability to see text and photos clearly on the computer display; and
  • Unwillingness to change hairstyle (e.g., braids, pony tails, dreadlocks) or remove wig to accommodate application of the EEG headset, if necessary.
  • Control participants:
  • Refusal or inability to consent;
  • Pregnant;
  • History of serious neurological illness (e.g., Chronic seizure disorder, Wernicke-Korsakoff Syndrome, Epilepsy, Any history of seizures, Other \[please specify\]);
  • Inability to see text and photos clearly on the computer display;
  • Current or previous problems using opioids, other prescription (prescribed or not prescribed) or illicit drugs;
  • Regular nicotine user (e.g., cigarette smoker, e-cig user) within the past 12 months; and
  • Unwillingness to change hairstyle (e.g., braids, pony tails, dreadlocks) or remove wig to accommodate application of the EEG headset, if necessary.

About Neurotype Inc.

Neurotype Inc. is a pioneering clinical trial sponsor dedicated to advancing neurological research and therapies. With a focus on innovative solutions for neurodegenerative diseases and mental health disorders, Neurotype leverages cutting-edge technology and a multidisciplinary approach to streamline the clinical trial process. The organization is committed to enhancing patient outcomes through rigorous scientific methodologies, collaboration with leading research institutions, and an emphasis on ethical practices. By fostering a patient-centric environment, Neurotype aims to accelerate the development of transformative treatments that address the complexities of neurological conditions.

Locations

Minneapolis, Minnesota, United States

Patients applied

0 patients applied

Trial Officials

Justin Anker, PhD

Principal Investigator

University of Minnesota

Scott Burwell, PhD

Study Director

Neurotype Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported